Edwards Lifesciences’ Post

The third quarter of 2023 catalysed transformative changes in the #MedTech world, laying the foundation for a safer and more patient-centric future. As we enter November, explore our quarterly editors' recap, spotlighting key highlights in funding, innovations, clinical trials, mergers, acquisitions, and regulatory approvals. 📎 https://lnkd.in/dpQaJain #EditorsChoice #MedTech #IndustryInsights #GuidedSolutions

How has 2023 panned out for the #lifesciences industry in Asia Pacific? Many of the trends in 2023 in life sciences in Asia Pacific were predicted, but there have been some unexpected events, which have caught market participants off-guard. It’s been the year of the expected and the surprises. Ben McLaughlin, Baker McKenzie, Australia; and Andrew Martin baker Principal, Baker McKenzie Wong & Leow’s Mergers & Acquisitions practice talk more about it. #artificialintelligence

MedTech Mergers & Acquisitions are expected to see a big uptick in 2024 and 2025. Are Johnson & Johnson potentially looking to add to their big-ticket acquisitions in the #Cardiovascular space? This comes off the back of their $16B Abiomed aquisition in late 2022, potentially bolstering their presence in this high value market segment. I'm sure there's lots more exciting changes coming in the coming couple of years. Watch this space. https://lnkd.in/exniAkyz

Spinal market consolidation has been real. But it also allowed new companies to be created. See below a document summarizing the acquisitions, since 2010, of the current 7 largest spinal companies. Did I miss anything? #spine #healthcare #mergersandacquisitions #privateequity Medtronic Globus Medical NuVasive DePuy Synthes Stryker Alphatec Spine ZimVie Spine Orthofix #wallstreet #M&A

Discover the trends and challenges the pharma industry is expected to face this year in Quanticate's recent article on World Pharma Today. With a surge in demand for complex treatments, the advancements of technology, mergers & acquisitions, and the incorporation of real world data reshaping the industry, success in the CRO market in 2024 will depend on the ability to adapt, innovate, and form strategic partnerships. Read the full article here👇 https://hubs.li/Q02mvjSn0

BD, Edwards, Acquisition

Surmodics to be Acquired by Private Equity Firm for $627M: Surmodics, Inc. announced that it agreed to be acquired by GTCR LLC, a #privateequity firm with #healthcare interests. Eden Prairie, Minnesota-based Surmodics company develops a range of technologies, including drug-coated balloons and thrombectomy systems. Its SurVeil DCB received a long-awaited FDA approval in June 2023. The #medicaldevice company also reported successful early clinical use of its Pounce LP thrombectomy system at the start of this year. Surmodics acquisition marks latest private equity play in #MedTech: With this deal, private equity firms continue to play a role on the medtech mergers and acquisitions scene. Medtech companies, including Medtronic and Baxter, previously looked to private equity for spinoff and separation opportunities. Firms also make significant investments, like one in Medline years ago. GTCR focuses on investing in companies in a number of industries, including healthcare and technologies. To date, its investments top $25 billion in more than 280 companies. It also currently manages $40 billion in equity capital. The firm’s Managing Director and Head of Healthcare, Sean Cunningham, said GTCR believes Surmodics is “well-positioned for attractive, long-term growth and value creation.”

Edwards Lifesciences is on a growth trajectory, investing $1.2 billion to acquire two innovative cardiac device companies. This strategic move expands their structural heart portfolio and addresses critical areas in cardiac care. The acquisitions include JenaValve Technology, which is pioneering a treatment for aortic regurgitation, and Endotronix, which offers an implantable pulmonary artery pressure sensor for heart failure. This announcement comes as Edwards reported a slowdown in their core TAVR business for Q2, which has affected their share prices. Despite this, the company remains optimistic about the future. They believe these new investments will drive long-term growth and enhance their presence in niche markets of aortic disease and heart failure treatment. Moreover, Edwards’ TMTT (transcatheter mitral and tricuspid therapies) segment has shown remarkable growth, with a 75% increase in sales year-over-year. This progress highlights their ability to innovate and adapt in a rapidly evolving medical landscape. These acquisitions are a testament to Edwards’ commitment to advancing healthcare solutions and addressing unmet needs in cardiac care. https://lnkd.in/dzXu8XVv #CardiacInnovation #MedTech #HealthcareLeadership

Noninvasive Treatment Provider Neuronetics Agrees To Merge With Canadian Firm Greenbrook TMS; Reports Q2 Earnings And Guidance Below Expectations https://ift.tt/RWfkTDq Neuronetics to acquire Greenbrook TMS (OTC: GBNHF) in an all-stock deal, doubling revenue to $145M. The combined company expects mid-teens growth in 2025 and 2026, with $15M in cost savings and positive EBITDA by 2025. Neuronetics to hold 57% ownership. read more via Benzinga - Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals https://ift.tt/7XSumTy August 12, 2024 at 02:12PM

Wolfteam Ltd. solves mergers and acquisitions, capital markets, corporate finance, valuations, market risk, AI, modelling in the fast growing, already large, middle income markets of Bulgaria, Central And Eastern Europe. Do contact Wolfteam Ltd. for a free consultation or deals, investing @: petar.posledovich@wolfteamedge.com +359 887 49 68 62 #mergersandacquisitions #capitalmarkets #corporatefinance #valuations #marketrisk #ai #modelling